CareFusion’s “Buy” Rating Reiterated at Bank of America (CFN)
CareFusion (NYSE:CFN)‘s stock had its “buy” rating restated by stock analysts at Bank of America in a report issued on Monday. They currently have a $43.97 price target on the stock, down from their previous price target of $50.00.
Several other analysts have also recently commented on the stock. Analysts at Raymond James reiterated a “strong-buy” rating on shares of CareFusion in a research note on Friday. They now have a $52.00 price target on the stock, up previously from $50.00. Separately, analysts at Piper Jaffray raised their price target on shares of CareFusion from $45.00 to $48.00 in a research note on Friday, August 8th. Finally, analysts at JPMorgan Chase & Co. raised their price target on shares of CareFusion from $44.00 to $48.00 in a research note on Friday, August 8th. Five equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $45.25.
Shares of CareFusion (NYSE:CFN) opened at 43.97 on Monday. CareFusion has a 52 week low of $35.01 and a 52 week high of $45.81. The stock’s 50-day moving average is $44.25 and its 200-day moving average is $41.78. The company has a market cap of $8.920 billion and a price-to-earnings ratio of 22.43.
CareFusion (NYSE:CFN) last announced its earnings results on Thursday, August 7th. The company reported $0.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.07. The company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the previous year, the company posted $0.55 earnings per share. The company’s revenue for the quarter was up 24.3% on a year-over-year basis. Analysts expect that CareFusion will post $2.67 EPS for the current fiscal year.
CareFusion Corporation (NYSE:CFN) is a global medical technology company.
Receive News & Ratings for CareFusion Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareFusion Co and related companies with Analyst Ratings Network's FREE daily email newsletter.